HeartCon Medical Nominated for 2025 Prix Galien USA 'Best Start-Up' Award Amid IPO Filing

Recently, The Galien Foundation announced2025 Prix Galien USA AwardNomination List. magAssist, with its continuous R&D achievements and clinical application performance in the field of artificial heart and life support technology, has successfully made it to the shortlist."Best Start-UpAward." This award is recognized as one of the most influential honors in the global life sciences and medical technology fields, aiming to acknowledge scientific innovations that significantly improve human health.

Internationally Recognized Life Science Awards

The Prix Galien Award, established in 1970 and named after Galen, the father of modern medicine, has been committed to promoting global medical innovation for over 50 years. It is known as the "Nobel Prize of the biopharmaceutical field."

Since its establishment in 2007, the Prix Galien USA has been judged by a panel consisting of Nobel laureates and several internationally renowned medical experts,Scientific Innovation,ClinicalValue and Patient BenefitsCore dimensions are evaluated without being influenced by the degree of commercialization or market size. Past winners include Novartis' CAR-T therapy Kymriah® and Abbott's Mitral Clip® cardiac interventional device, both of which have led transformative changes in treatment models within their respective fields.

Bruno Cohen, Chairman of the Galien Foundation, said: "The progress in the life sciences over the past year has been exciting, these nominated projects demonstrate the continuously accelerating trend of healthcare innovation, bringing hope to future patients."

Highlights of the 2025 Nominations

The 2025 Prix Galien USA has been established.Best Digital Health Solution、Best Medical Technology、Incubator/Accelerator and Equity SupportAndBest StartupFour award categories, with nominated companies covering innovative forces worldwide. Well-known companies such as Abbott, Empatica, Recursion, and Oura are also on the nomination list, demonstrating the intensity of this year's competition and industry standards.

In the "Best Start-up" category, 53 emerging companies have been shortlisted, covering cutting-edge fields such as AI-assisted diagnosis and treatment, advanced medical devices, cell and gene therapies, and wearable monitoring.

The Technology and Clinical Value Behind the Nomination

magAssist has long been committed toArtificial Heart and Full-process Life Support PlatformResearch and development, with core products including:

• MoyoAssist® Extracorporeal Ventricular Assist Device (ExtracorporealVAD）: It has been applied in many large Class III hospitals in China, providing stable circulatory support for high-risk PCI, acute heart failure, and complex cardiovascular surgery patients, improving intraoperative hemodynamics, and buying precious time for patients waiting for organ transplantation or cardiac function recovery.

• NyokAssist® Percutaneous, Foldable, Minimally Invasive Pathway Intervention Short-Term Assist DeviceVAD）: With its innovative design and minimally invasive advantages, it has brought new possibilities for short-term cardiac assist therapy and has been grantedFDA Breakthrough DeviceRecognized for bringing potential significant clinical benefits to critically ill patients.

• BreathMo® Portable Magnetic Levitation Extracorporeal Membrane Oxygenation (ECMO) System:The full magnetic levitation system provides better blood compatibility, with dual indications for extracorporeal ventricular assist and extracorporeal membrane oxygenation, closely mimicking the lung function of the human body.

  
  

International Influence and Future Prospects

Being shortlisted for the 2025 Prix Galien USA Award means that magAssist's technical approach, clinical outcomes, and development potential have been recognized by international experts.

The 2025 Prix Galien USA Awards Ceremony will be held onOctober 30Held at the American Museum of Natural History in New York, the event will bring together the world's top medical technology innovators to witness the announcement of the annual award-winning projects.

magAssist will continue to drive scientific innovation as its core, advance the research, development, and application of artificial heart and life support platforms, and commit to providing safer, more efficient, and accessible treatment options for critically ill patients worldwide.

- END -